Table 1: Reported cases of t-APL in patients treated with RAI therapy with underlying cytogenetic abnormalities.
| Case | Year | Authors | Age | Sex | RAI dose (mCi) | Interval between RAI to APL (years) | Cytogenetic abnormalities | Survival after diagnosis of t-APL |
| 1 | 1993 | Richards EM, et al. [3] | 28 | M | 6210 | 1.2 | t(15;17) | - |
| 2 | 1998 | Roldan Schilling V, et al. [4] | 43 | F | 150 | 5 | t(15;17) | 2 years |
| 3 | 2006 | Lee SH, et al. [5] | 48 | F | 676 | 1 | t(15;17) Trisomy 8 | Unknown |
| 4 | 2007 | Grudeva-Popova J, et al. [6] | 47 | F | 118 | 1.2 | t(15;17) (q22;21) | - |
| 5 | 2012 | Gilabert M, et al. [7] | 39 | F | N/A | 2 | t(15;17) | N/A |
| 6 | 2016 | Oluwasanjo A [8] | 35 | F | 103 | 1.5 | t(15;17); (q22;q21.2) | - |
| 7 | 2016 | Current case | 60 | F | 202.5 | 2 | t(15;17), Trisomy 8, Interstitial 9q deletion | < 1 week |
Search Strategy: We performed a MEDLINE search of patients with therapy related myeloid neoplasms from 1990 to 2017. The keywords used in the search were radioactive iodine, therapy related, myeloid neoplasm, promyelocytic leukemia, cytogenetic abnormalities and 9q deletion.